Abstract:

Neovascular glaucoma (NVG) is a severe complication of ocular ischemia diseases. High concentration of vascular endothelial growth factor (VEGF) exists in anterior segment which leads to iris neovascularization. Aqueous humor outflow will be blocked. Anti-VEGF agent can combine with VEGF receptor and block VEGF,  and to a certain extent delay the appearance of iris neovascularization. Intravitreal or intracameral injection of anti-VEGF agents (such as bevacizumab, ranibizumab and so on) combined with the traditional treatment such as trabecutectomy, glaucoma valve implantation, vitrectomy, panretinal photocoagulation are good choices to treat neovascular glaucoma.  (Int Rev Ophthalmol,  2015,  39:     376-381)